Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 204 abstracts

no pagination
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr;15(2):e155-8.
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54.   PMCID: PMC4898971
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Nov 05;373(19):1803-13.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May;33(13):1430-7.   PMCID: PMC4806782
Najjar M, Suebsuwong C, Ray S, Thapa R, Maki J, Nogusa S, Shah S, Saleh D, Gough P, Bertin J, Yuan J, Balachandran S, Cuny G, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Reports. 2015 Mar 24;10(11):1850-60.   PMCID: 4494889
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M, Su Y, Russo IH, Himmelberger JA, Slifker M, Manni A, Russo J. Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121-7.   PMCID: 4948656
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell cycle (Georgetown, Tex). 2015 Aug;14(15):2422-8.   PMCID: PMC4614396
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan 10;33(2):156-64.   PMCID: PMC4279235
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Clin Genitourin Cancer. 2015 Apr;13(2):142-9.
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov;99(11):1731-7.   PMCID: 4222464
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents Female therapeutic use drug therapy Middle Aged Male pathology Aged Adult mortality therapy adverse effects metabolism administration & dosage drug effects antagonists & inhibitors Monoclonal Antibodies Cisplatin Survival Analysis genetics pharmacology Drug Dose-Response Relationship methods Tumor Cell Line Neoadjuvant Therapy Renal Cell Carcinoma Drug Administration Schedule Kidney Neoplasms analogs & derivatives Signal Transduction immunology Kaplan-Meier Estimate Chemoradiotherapy Treatment Outcome Immunotherapy 80 and over Aged Young Adult Inbred C57BL Mice Taxoids Neoplasms secondary Cell Proliferation Prospective Studies Neoplasm Drug Resistance Lung Neoplasms biosynthesis Prognosis Mice Ovarian Neoplasms CD274 Antigens Clinical Trials as Topic Squamous Cell Carcinoma Non-Small-Cell Lung Carcinoma Head and Neck Neoplasms Maximum Tolerated Dose Disease-Free Survival Tumor Biomarkers Protein Kinase Inhibitors Molecular Targeted Therapy Triple Negative Breast Neoplasms antagonists & Janus Kinases Folic Acid Clear Cell Adenocarcinoma Mutation Neoplastic Stem Cells Internet Molecular Docking Simulation Rb1 Urothelial carcinoma epidemiology Trail Reed-Sternberg Cells Targeted therapy Unsaturated Fatty Acids blood Camptothecin Disease Progression TNF-related apoptosis-inducing ligand TRAIL Leucovorin Breast Neoplasms Hydroxamic Acids Onc201 DNA Repair lymphoma Dose Fractionation CTLA-4 Antigen Intravenous Administration Finland non-Hodgkin's lymphoma NHL Canada Capecitabine Half-Life Salvage Therapy Proportional Hazards Models Ubiquitin-Protein Ligases T-Lymphocyte Subsets Nhl Pyridazines deficiency Prostatic Neoplasms Follow-Up Studies Viral Load Paclitaxel Imidazoles Preclinical Drug Evaluation Jurkat Cells Amino Acid Sequence Radiotherapy Dosage ErbB-2 Receptor Rectal Neoplasms Brain Neoplasms AIDS-Related Lymphoma Epidermal Growth Factor Receptor TOR Serine-Threonine Kinases Italy Radiotherapy HEK293 Cells Urinary Bladder Neoplasms Blood-Brain Barrier Cell Survival Atm Combination Drug Therapy Cell Cycle Proteins Multiprotein Complexes Quinazolines Tic10 Adolescent Fluorouracil Fancc Cultured Tumor Cells Therapeutic targets Rituximab Cytarabine United States Neutropenia Neoplasm Transplantation Interferon-gamma Androgen Antagonists Hodgkin Disease Antineoplastic Combined Chemotherapy Protocols Capillary Permeability Monoclonal Antibodies-Murine-Derived Natural products BRCA1 Genes Biomarkers diagnosis Cancer stem cells chemically induced Heterozygote
Last updated on Wednesday, July 08, 2020